3 Ways Ariad Pharmaceuticals Can Salvage Iclusig
Iclusig has taken quite a few knocks since October, but there are three ways Ariad could rebuild the brand's value and boost shareholder value in the process.
Here's What These Slow-and-Steady $3 Billion Investors Are Buying
You can get some promising investment ideas by keeping an eye on big investors.
Celgene Corporation: Fast Growing Drugs About to Become Blockbusters in 2014
Thanks to a new indication for treating pancreatic cancer, Celgene's (CELG) Abraxane may be poised to reach blockbuster status this year